GlassScriptPhysician profile
Ellen H Tessman
NPI 1316961626
$4,612.82
in general payments reported to CMS, 2019-2025
33 companies · $721 in 2025
The $721 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $734 · 2022: $870 · 2023: $1,200 · 2024: $1,088 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,966 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,966.33 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $842.12 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Abbvie INC. | $603.91 | 2021-2025 | |
| Insulet Corporation | $368.02 | 2021-2025 | Omnipod |
| Medtronic, INC. | $351.44 | 2023-2024 | Minimed 780g |
| Dexcom, INC. | $261.09 | 2021-2024 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Sequel Med Tech, LLC | $254.33 | 2025 | Twiist |
| Sanofi-Aventis U.S. LLC | $192.43 | 2023-2024 | |
| Novo Nordisk INC | $181.03 | 2021-2025 | Sogroya |
| Tandem Diabetes Care, INC. | $168.70 | 2021-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Azurity Pharmaceuticals, INC. | $138.61 | 2022-2024 | Triptodur, Triptodur |
| Xeris Pharmaceuticals, INC. | $138.01 | 2021-2025 | Gvoke Hypopen |
| Mannkind Corporation | $136.32 | 2024-2025 | |
| Endo Pharmaceuticals INC. | $136.13 | 2021-2024 | Supprelin |
| Ascendis Pharma Endocrinology INC | $118.63 | 2023-2025 | Skytrofa |
| Zealand Pharma US, INC. | $111.66 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $70.86 | 2022-2025 | Strensiq |
| Regeneron Healthcare Solutions, INC. | $68.84 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $58.15 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $45.73 | 2022-2024 | Imcivree, Imcivree |
| Endo USA, INC. | $42.81 | 2024-2025 | Supprelin |
| Arbor Pharmaceuticals, INC. | $42.68 | 2021-2022 | |
| Kyowa Kirin, INC. | $35.05 | 2023-2025 | Crysvita |
| Eton Pharmaceuticals, INC. | $30.57 | 2021-2023 | Alkindi |
| Organon LLC | $26.37 | 2025 | Nexplanon |
| Ani Pharmaceuticals, INC. | $25.77 | 2024 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $25.00 | 2024 | Acthar |
| Beta Bionics, INC. | $23.82 | 2023 | Ilet Bionic Pancreas |
| Amneal Pharmaceuticals LLC | $23.06 | 2022 | |
| Biomarin Pharmaceutical INC. | $22.90 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $20.01 | 2022 | |
| Ibsa Pharma INC. | $18.19 | 2025 | Flector, Licart, Tirosint |
| Soleno Therapeutics, INC. | $16.26 | 2025 | Vykat Xr |
| Lilly USA, LLC | $14.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Tessman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.